EI
SBBP

EAM Investors’s Strongbridge Biopharma plc. SBBP Stock Holding History

EAM Investors’s Portfolio SBBP Stock Details SBBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-76,595
Closed -$678K – 384
2018
Q1 		$678K Buy
+76,595
New +$573K 0.11% 243

Other funds holding SBBP

CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
HCS
Harvest Capital Strategies San Francisco, California $73.7M AUM 7.47% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

EAM Investors's SBBP Position: Q2 2018 in Review

EAM Investors sold out of Strongbridge Biopharma plc. (SBBP) in Q2 2018, closing a stake of 76,595 shares — an estimated $678K sold.

EAM Investors first reported a position in SBBP in Q1 2018 and held it in 1 quarter. The position peaked at $678K in Q1 2018. 64 funds tracked by Wall St. Rank hold SBBP as of Q2 2018.

  • EAM Investors reported no remaining Strongbridge Biopharma plc. position as of Q2 2018 after selling out during the quarter.
  • EAM Investors sold 76,595 Strongbridge Biopharma plc. shares in Q2 2018, an estimated $678K.
  • EAM Investors first reported a position in Strongbridge Biopharma plc. in Q1 2018 and held it in 1 quarter.
  • EAM Investors's Strongbridge Biopharma plc. position peaked at $678K in Q1 2018.
  • 64 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q2 2018.

Based on EAM Investors's 13F filing for Q2 2018, filed 3 Aug 2018.